Retension Pharmaceuticals (NASDAQ:RTSN) Director Franklin Berger Acquires 10,000 Shares of Company Stock

Retension Pharmaceuticals, Inc. (NASDAQ:RTSN) Director Franklin Berger acquired 10,000 shares of the stock in a transaction dated Tuesday, October 13th. The shares were bought at an average cost of $12.00 per share, for a total transaction of $120,000.00. Following the acquisition, the director owned 10,000 shares in the company, valued at $120,000. The trade was a ? increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Retension Pharmaceuticals Stock Up 2.7%

Shares of RTSN stock opened at $11.63 on Wednesday. Retension Pharmaceuticals, Inc. has a twelve month low of $9.66 and a twelve month high of $12.50.

Retension Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.